Future Perspectives on Drug Targeting in Adult T Cell Leukemia-Lymphoma

Francesca Marino-Merlo, Antonio Mastino, Sandro Grelli, Olivier Hermine, Ali Bazarbachi, Beatrice Macchi

Research output: Contribution to journalReview articlepeer-review


Human T cell leukemia virus type 1 (HTLV-1) is the etiological agent of adult T cell leukemia/lymphoma (ATL), HTLV-1 associated myelopathy (HAM/TSP), and of a number of inflammatory diseases with an estimated 10-20 million infected individuals worldwide. Despite a number of therapeutic approaches, a cure for ATL is still in its infancy. Conventional chemotherapy has short-term efficacy, particularly in the acute subtype. Allogeneic stem cell transplantation offers long-term disease control to around one third of transplanted patients, but few can reach to transplant. This prompted, over the past recent years, the conduction of a number of clinical trials using novel treatments. Meanwhile, new data have been accumulated on biological and molecular bases of HTLV-1 transforming and infecting activity. These data offer new rational for targeted therapies of ATL. Taking into account the double-face of ATL as an hematologic malignancy as well as a viral infectious disease, this Mini-Review seeks to provide an up-to-date overview of recent efforts in the understanding of the mechanisms involved in already used therapeutic regimens showing promising results, and in selecting novel drug targets for ATL.

Original languageEnglish
Article number925
JournalFrontiers in Microbiology
Publication statusPublished - May 9 2018


Dive into the research topics of 'Future Perspectives on Drug Targeting in Adult T Cell Leukemia-Lymphoma'. Together they form a unique fingerprint.

Cite this